NCT06282978
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06282978
Title Phase II Study of Elranatamab as Single Agent for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors PETHEMA Foundation
Indications
Therapies
Age Groups: adult | senior
Covered Countries ESP

Facility Status City State Zip Country Details
Hospital Clínico Universitario de Santiago ~ CHUS Santiago de Compostela A Coruña 15706 Spain Details
Hospital Son Llàtzer Palma de Mallorca Balearic Islands 07198 Spain Details
Institut Catala d'Oncologia (ICO) Badalona - Hospital Universitari Germans Trias i Pujol Badalona Barcelona 08916 Spain Details
Hospital Universitario Marqués de Valdecilla Santander Cantabria 39008 Spain Details
Hospital Universitario de Jerez de la Frontera Jerez de la Frontera Cádiz 11407 Spain Details
CHU de Gran Canaria Doctor Negrín Las Palmas de Gran Canaria Las Palmas 35010 Spain Details
Hospital Clínico Universitario Virgen de la Arrixaca El Palmar Murcia 30120 Spain Details
H. Clínic i Provincial de Barcelona Barcelona 08036 Spain Details
Hospital de Cabueñes Gijón 33394 Spain Details
Complejo Asistencial Universitario de León León Spain Details
Hospital Universitario Lucus Augusti Lugo Spain Details
Hospital Clínico Universitario Salamanca Salamanca 37007 Spain Details
C.H. de Toledo (Virgen de la Salud) Toledo 45005 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field